4,405 Shares in Cencora, Inc. (NYSE:COR) Bought by Fulton Bank N.A.

Fulton Bank N.A. purchased a new position in Cencora, Inc. (NYSE:COR) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,405 shares of the company’s stock, valued at approximately $1,070,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. acquired a new stake in Cencora in the 4th quarter worth $4,212,508,000. PNC Financial Services Group Inc. acquired a new stake in Cencora in the 4th quarter worth $51,339,000. Los Angeles Capital Management LLC acquired a new stake in Cencora in the 1st quarter worth $45,692,000. Ferguson Wellman Capital Management Inc. acquired a new stake in Cencora in the 1st quarter worth $32,609,000. Finally, Park National Corp OH acquired a new stake in Cencora in the 1st quarter worth $5,947,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on COR. Robert W. Baird lifted their target price on shares of Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Citigroup lifted their target price on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. SVB Leerink began coverage on shares of Cencora in a research report on Monday, February 26th. They set an “outperform” rating and a $261.00 target price on the stock. Finally, Leerink Partnrs restated an “outperform” rating on shares of Cencora in a research report on Monday, February 26th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $233.90.

Insider Buying and Selling

In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the sale, the insider now owns 24,418,171 shares of the company’s stock, valued at $5,252,836,945.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cencora news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the completion of the sale, the insider now owns 24,418,171 shares of the company’s stock, valued at $5,252,836,945.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Robert P. Mauch sold 57,564 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the completion of the sale, the chief operating officer now directly owns 24,412 shares of the company’s stock, valued at approximately $5,739,017.08. The disclosure for this sale can be found here. Insiders sold a total of 1,956,675 shares of company stock valued at $422,352,056 over the last ninety days. Insiders own 15.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR traded down $1.52 during trading on Thursday, reaching $235.68. The company had a trading volume of 1,182,338 shares, compared to its average volume of 1,337,936. Cencora, Inc. has a 52 week low of $171.65 and a 52 week high of $246.75. The stock has a market cap of $47.01 billion, a PE ratio of 25.79, a PEG ratio of 1.65 and a beta of 0.48. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The business’s 50 day moving average price is $229.45 and its 200-day moving average price is $226.49.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. The business had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. Cencora’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.50 earnings per share. Analysts expect that Cencora, Inc. will post 13.44 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were paid a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is 22.32%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.